Literature DB >> 21422205

Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.

Catharine C Bulik1, David P Nicolau.   

Abstract

The limited treatment options available for carbapenemase-producing Klebsiella pneumoniae (KPC) have made it a formidable pathogen. Previously we have shown the enhanced activity of pharmacodynamically optimized doripenem against KPC. Capitalizing on KPC's increased affinity for ertapenem, we evaluated the efficacy of a combination of ertapenem and doripenem in both an in vitro chemostat and an in vivo murine thigh infection model. Overall, the combination of doripenem plus ertapenem demonstrated enhanced efficacy over either agent alone.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21422205      PMCID： PMC3101469          DOI： 10.1128/AAC.01420-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Health and economic impacts of antimicrobial resistance.

Authors:  S D Holmberg; S L Solomon; P A Blake
Journal:  Rev Infect Dis       Date:  1987 Nov-Dec

2.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

3.  Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin.

Authors:  K Kontopoulou; E Protonotariou; K Vasilakos; M Kriti; A Koteli; E Antoniadou; D Sofianou
Journal:  J Hosp Infect       Date:  2010-06-17       Impact factor: 3.926

4.  Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary.

Authors:  A Tóth; I Damjanova; E Puskás; L Jánvári; M Farkas; A Dobák; K Böröcz; J Pászti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-18       Impact factor: 3.267

5.  In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

6.  In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

7.  Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns.

Authors:  Khetam Hussein; Hanna Sprecher; Tania Mashiach; Ilana Oren; Imad Kassis; Renato Finkelstein
Journal:  Infect Control Hosp Epidemiol       Date:  2009-07       Impact factor: 3.254

8.  Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.

Authors:  C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Mariana Castanheira; Hélio S Sader; Lalitagauri M Deshpande; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

10.  Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).

Authors:  Paul R Rhomberg; Lalitagauri M Deshpande; Jeffrey T Kirby; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2007-07-26       Impact factor: 2.803
View more
  72 in total

1.  Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae.

Authors:  Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2012-07       Impact factor: 5.191

Review 2.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

3.  Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae.

Authors:  Helen Giamarellou; Lambrini Galani; Fotini Baziaka; Ilias Karaiskos
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

4.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

5.  Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Jose F Camargo; Jacques Simkins; Thiago Beduschi; Akin Tekin; Laura Aragon; Armando Pérez-Cardona; Clara E Prado; Michele I Morris; Lilian M Abbo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-10       Impact factor: 5.191

6.  Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States.

Authors:  Pia S Pannaraj; Jennifer Dien Bard; Chiara Cerini; Scott J Weissman
Journal:  Pediatr Infect Dis J       Date:  2015-01       Impact factor: 2.129

7.  KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.

Authors:  Mao Hagihara; Jared L Crandon; Carl M Urban; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

9.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.